In this study, we report that NL101 is highly active against B cell lymphomas such as DLBCL and BL, and NL101 significantly inhibits the expression of miR-21, which promotes lymphoma cell survival through modulating c-Myc/Mxd1 axis. Here, MYC is linked to B-cell non-Hodgkin lymphoma.